M. Eisenberger

Publications583
h-index86
Citations40,624
Highly Influential Citations1,436
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • E. Antonarakis
  • 607 Publications • 18,537 Citations
  • H. Scher
  • 1,137 Publications • 104,575 Citations
  • M. Carducci
  • 789 Publications • 42,608 Citations
  • K. Fizazi
  • 1,005 Publications • 52,457 Citations
  • Publications
  • Influence
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
TLDR
When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plusprednisone.
View on PubMed
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
BACKGROUND The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a…
View on PubMed
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
TLDR
Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone.
View on PubMed
Natural history of progression after PSA elevation following radical prostatectomy.
TLDR
Several clinical parameters help predict the outcomes of men with PSA elevation after radical prostatectomy, and these data may be useful in the design of clinical trials, the identification of men for enrollment into experimental protocols, and counseling men regarding the timing of administration of adjuvant therapies.
View on PubMed
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
TLDR
New consensus criteria for eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone are defined, with increasing emphasis on time-to-event end points as decision aids in proceeding from phase II to phase III trials.
View on PubMed
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
View via Publisher
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
View on PubMed
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
TLDR
It is confirmed that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP, and consistent results are observed across subgroups of patients.
View on PubMed
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
TLDR
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade.
View on PubMed
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
TLDR
The purpose of determining the number of patients whose PSA level drops in a phase II trial of AIPC is to guide the selection of agents for further testing and phase III trials and developed practical guidelines for using PSA as a measurement of outcome.
View on PubMed
...
...